The global recurrent glioblastoma multiforme treatment
market was valued at USD 370.6 million in 2022, and a CAGR of 7.5% is expected
during the forecast period. Glioblastoma is a type of brain tumor that arises
from supportive brain tissue called glioma. Increasing incidences of brain
tumors and neurological disorders are driving growth in this market
significantly.
The occurrence of Glioblastoma specially in older population is
driving growth in this market significantly. Continuous research and
development in oncology is driving growth in this market significantly.
Increasing demand for targeted therapies, immunotherapies, and personalized
medicine is driving the demand in the market.
Growth Drivers
Precision medicine is gaining traction in oncology, with
therapies tailored to individual patients’ profiles based on genetic markers.
This approach is increasingly applied to recurrent GBM, which is highly
heterogeneous and the worst form of brain cancer. Governments, research
institutes, and pharmaceutical companies are investing significantly in cancer
research, particularly in areas with unmet medical needs like recurrent GBM.
This influx of funding is expected to accelerate the development of new and more
effective treatments.
Increasing health awareness and early diagnosis about
brain cancer have contributed to more accurate diagnoses. Although recurrent
GBM is difficult to treat, early diagnosis of the disease makes the treatment
possible. New drug approvals and launches for new treatments are driving growth
in the market significantly. Rising disposable income and a hectic life
schedule are driving growth significantly in the market. However, a lack of
effective therapies is hindering the growth in the market.
Segmentation
By Type
·
Grade 2
·
Grade 3
·
Grade 4
·
Others
By Treatment
·
Chemotherapy
·
Oral Medications
·
Radiosensitizers
·
Nitrosoureas Drugs
Regional Outlook
·
Asia Pacific
·
North America
·
Latin America
·
Middle East and Africa
·
Europe
Recurrent Glioblastoma Multiforme
Treatment Market by Type
On the basis of the type, the Recurrent Glioblastoma
Multiforme Treatment Market is segmented into Grade 2, Grade 3, and Grade 4.
The grade 4 segment is the leading segment because it is the most common and
deadly type of brain tumor, particularly among adults. Most patients diagnosed
with the disease fall into this category.
Grade 4 glioblastoma tends to occur
more frequently than lower-grade tumors, leading to a higher demand for
treatment options. Because of its aggressive nature, Grade 4 GBM typically
requires more intensive and multimodal treatment approaches, including surgery,
radiation, chemotherapy, and targeted therapies. Most clinical trials and
research efforts are concentrated on Grade 4 GBM due to its poor prognosis and
the high unmet medical need for effective treatment.
Governments, research
institutes, and pharmaceutical companies are investing significantly in cancer
research, particularly in areas with unmet medical needs like recurrent GBM.
This influx of funding is expected to accelerate the development of new and
more effective treatments. Increasing health awareness and early diagnosis
about brain cancer have contributed to more accurate diagnoses.
Regional Outlook
On the basis of the regions, the recurrent glioblastoma
multiforme treatment market is segmented into 5 regions: Asia Pacific, North
America, Latin America, the Middle East and Africa, and Europe. North America
is the leading segment in the market and is expected to dominate the market
during the forecast period due to well-established healthcare infrastructure
and increasing awareness about health and hygiene. Due to the presence of major
companies in the region, the United States is the leading market.
The region
has one of the most advanced healthcare systems in the world, with access to
cutting-edge technology, diagnostic tools, and treatment for complex diseases
like GBM. Glioblastoma is one of the most common forms of brain cancer, which
is the worst. High incidence rates create demand for better treatment and a
large patient population. The U.S. is home to many pharmaceuticals and research
companies that are heavily investing in cancer research. Relatively high
incidence of glioblastoma cases, contributing to a larger patient population in
need of treatment.
North America has one of the most developed healthcare
systems globally, with access to cutting-edge medical technologies, clinical
trials, and specialized care centers. The U.S. FDA provides fast-track
breakthrough therapy for the approval of drugs that address unmet medical
needs. The region has higher per capita healthcare expenditure, allowing
patients better access to expensive cutting-edge therapies and clinical trials
for recurrent GBM. Asia Pacific is another leading region in the market due to
the presence of countries like China, Japan, and India.
These countries are
leading to better access to treatment for conditions like GBM. The incidence of
glioblastoma is increasing in some parts of Asia-Pacific due to factors such as
aging population populations and better diagnostic capabilities. Increased
awareness of cancer and neurological disorders is also driving demand for
specialized treatment. Countries like Japan, South Korea, and India are
emerging for clinical trials and research in oncology. Asia Pacific is the
region where treatment is possible in a cheap and affordable way in comparison
to Europe and North America.
China and India have a large population base and
are showing an increased focus on improving cancer care, which is expected to
drive future growth. Europe has a well-established healthcare system, with many
countries providing universal healthcare, which facilitates access to advanced
treatments. Countries like Germany, the United Kingdom, France, and Italy are
major contributors to the GBM treatment market in this region. Various European
governments have launched initiatives and provided funding for cancer research,
which includes glioblastoma treatment.
Europe has a strong network of clinical
trial centers, which allows patients to access innovative treatment at an early
stage. Western European countries, where the medical infrastructure is more
advanced, are driving growth in the market significantly. The increasing
incidence of brain cancers is driving growth in the market significantly.
Rising approval and launch of novel treatments are driving growth in the
market. The presence of key players in the market is significantly driving the
growth in the market. Increasing health awareness about chronic diseases is driving
growth in the market significantly.
Key Players
·
GlaxoSmithKline Plc
·
F.Hoffman-La Roche Ltd
·
Pfizer Inc.
·
Merck Inc.
·
Bristol Myers Squibb
·
Elli Lilly and Company
·
Coherus Biosciences Inc.
·
ImmunoCellular Therapeutics
·
Cortice Bioscience Inc
·
Boston Biomedical
·
Genzyme Corporation
·
Other Players
Specifications |
Descriptions |
No Specifications |